Ryan D Gillis1, Edoardo Botteri2, Aeson Chang1, Alexandra I Ziegler1, Ni-Chun Chung1, Cindy K Pon1, David M Shackleford3, Bettina K Andreassen4, Michelle L Halls1, Jillian G Baker5, Erica K Sloan6. 1. Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Science, Monash University, Parkville, VIC, 3052, Australia. 2. Department of Research, Cancer Registry of Norway, Oslo, Norway; Section for Colorectal Cancer Screening, Cancer Registry of Norway, Oslo, Norway. 3. Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Science, Monash University, Parkville, VIC, 3052, Australia. 4. Department of Research, Cancer Registry of Norway, Oslo, Norway. 5. Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom. 6. Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Science, Monash University, Parkville, VIC, 3052, Australia; Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, VIC, 3000, Australia. Electronic address: erica.sloan@monash.edu.
Abstract
PURPOSE: The sympathetic nervous system drives breast cancer progression through β-adrenergic receptor signalling. This discovery has led to the consideration of cardiac β-blocker drugs as novel strategies for anticancer therapies. Carvedilol is a β-blocker used in the management of cardiovascular disorders, anxiety, migraine and chemotherapy-induced cardiotoxicity. However, little is known about how carvedilol affects cancer-related outcomes. METHODS: To address this, we investigated the effects of carvedilol on breast cancer cell lines, in mouse models of breast cancer and in a large cohort of patients with breast cancer (n = 4014). RESULTS: Treatment with carvedilol blocked the effects of sympathetic nervous system activation, reducing primary tumour growth and metastasis in a mouse model of breast cancer and preventing invasion by breast cancer cell lines. A retrospective analysis found that women using carvedilol at breast cancer diagnosis (n = 136) had reduced breast cancer-specific mortality compared with women who did not (n = 3878) (5-year cumulative incidence of breast cancer deaths: 3.1% versus 5.7%; p = 0.024 and 0.076 from univariate and multivariable analyses, respectively) after a median follow-up of 5.5 years. CONCLUSIONS: These findings provide a rationale to further explore the use of the β-blocker carvedilol as a novel strategy to slow cancer progression.
PURPOSE: The sympathetic nervous system drives breast cancer progression through β-adrenergic receptor signalling. This discovery has led to the consideration of cardiac β-blocker drugs as novel strategies for anticancer therapies. Carvedilol is a β-blocker used in the management of cardiovascular disorders, anxiety, migraine and chemotherapy-induced cardiotoxicity. However, little is known about how carvedilol affects cancer-related outcomes. METHODS: To address this, we investigated the effects of carvedilol on breast cancer cell lines, in mouse models of breast cancer and in a large cohort of patients with breast cancer (n = 4014). RESULTS: Treatment with carvedilol blocked the effects of sympathetic nervous system activation, reducing primary tumour growth and metastasis in a mouse model of breast cancer and preventing invasion by breast cancer cell lines. A retrospective analysis found that women using carvedilol at breast cancer diagnosis (n = 136) had reduced breast cancer-specific mortality compared with women who did not (n = 3878) (5-year cumulative incidence of breast cancer deaths: 3.1% versus 5.7%; p = 0.024 and 0.076 from univariate and multivariable analyses, respectively) after a median follow-up of 5.5 years. CONCLUSIONS: These findings provide a rationale to further explore the use of the β-blocker carvedilol as a novel strategy to slow cancer progression.
Authors: Md Abdullah Shamim; Steven Yeung; Ayaz Shahid; Mengbing Chen; Jeffrey Wang; Preshita Desai; Cyrus Parsa; Robert Orlando; Frank L Meyskens; Kristen M Kelly; Bradley T Andresen; Ying Huang Journal: Int J Pharm Date: 2021-11-15 Impact factor: 5.875
Authors: M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou Journal: Cell Commun Signal Date: 2021-07-20 Impact factor: 5.712
Authors: Ahlam M Alhusaini; Laila M Fadda; Abeer M Alanazi; Wedad S Sarawi; Hatun A Alomar; Hanaa M Ali; Iman H Hasan; Rehab Ahmed Ali Journal: Front Pharmacol Date: 2022-02-25 Impact factor: 5.810
Authors: Jennifer Maning; Victoria L Desimine; Celina M Pollard; Jennifer Ghandour; Anastasios Lymperopoulos Journal: Int J Mol Sci Date: 2022-09-26 Impact factor: 6.208